Unknown NA INTERVENTIONAL 1-arm NCT04945057

AKTIBIPO-VALIDATION: A Study to Validate Benefits of Mindpax System in Managing Bipolar Disorder (VAL1M)

Sponsor: Mindpax s.r.o., Czech Republic

Updated 5 times since 2021 Last updated: Oct 13, 2022 Started: May 5, 2021 Primary completion: Oct 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Bipolar Disorder, this trial is ongoing. The trial is conducted by Mindpax s.r.o., Czech Republic and has accumulated 5 data snapshots since 2021. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Oct 2024 — Present [monthly]

Unknown NA

Status: Active Not Recruiting → Unknown
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting NA
Nov 2022 — Jul 2024 [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting
Sep 2021 — Nov 2022 [monthly]

Recruiting NA

First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mindpax s.r.o., Czech Republic
National Institute of Mental Health, Czech Republic

Data source: National Institute of Mental Health, Czech Republic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Klecany, Czechia